EU regulators in April gave the green light to Europe's first "biosimilar" drug, the human growth hormone Omnitrope produced by Novartis subsidiary Sandoz. The drug is a generic for Pfizer's Genotropin and is expected to hit European markets shortly. Around the same time that Sandoz got its EU approval, a US federal judge ordered the Food & Drug Administration to rule on Sandoz's new drug application for Omnitrope, which the company had submitted in 2003.













